Your browser doesn't support javascript.
loading
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Brahmer, Julie R; Abu-Sbeih, Hamzah; Ascierto, Paolo Antonio; Brufsky, Jill; Cappelli, Laura C; Cortazar, Frank B; Gerber, David E; Hamad, Lamya; Hansen, Eric; Johnson, Douglas B; Lacouture, Mario E; Masters, Gregory A; Naidoo, Jarushka; Nanni, Michele; Perales, Miguel-Angel; Puzanov, Igor; Santomasso, Bianca D; Shanbhag, Satish P; Sharma, Rajeev; Skondra, Dimitra; Sosman, Jeffrey A; Turner, Michelle; Ernstoff, Marc S.
Afiliação
  • Brahmer JR; Department of Oncology and the Thoracic Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland, USA.
  • Abu-Sbeih H; Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Ascierto PA; Unit of Melanoma Cancer Immunotherapy and Innovative Therapy, National Tumour Institute IRCCS Fondazione 'G. Pascale', Napoli, Italy.
  • Brufsky J; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Cappelli LC; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Cortazar FB; Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Gerber DE; New York Nephrology Vasculitis and Glomerular Center, Albany, New York, USA.
  • Hamad L; Department of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Hansen E; Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Johnson DB; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Lacouture ME; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
  • Masters GA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Naidoo J; Department of Medicine, Helen F. Graham Cancer Center, Newark, Delaware, USA.
  • Nanni M; Department of Oncology and the Thoracic Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland, USA.
  • Perales MA; Department of Oncology, Beaumont Hospital Dublin, The Royal College of Surgeons of Ireland, Dublin, Ireland.
  • Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Santomasso BD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Shanbhag SP; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Sharma R; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Skondra D; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Sosman JA; Cancer Specialist of North Florida, Fleming Island, Florida, USA.
  • Turner M; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Ernstoff MS; Department of Ophthalmology and Visual Science, University of Chicago Medical Center, Chicago, Illinois, USA.
J Immunother Cancer ; 9(6)2021 06.
Article em En | MEDLINE | ID: mdl-34172516
ABSTRACT
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sociedades Médicas / Guias como Assunto / Inibidores de Checkpoint Imunológico / Imunoterapia / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sociedades Médicas / Guias como Assunto / Inibidores de Checkpoint Imunológico / Imunoterapia / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos